Intellectual property
BrainStorm holds an intellectual property portfolio covering the NurOwn technology platform.
04
Rights and licensing
BrainStorm holds rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive, worldwide licensing agreement.
Read next
- 01
Autologous cellular therapy
Why a therapy grown from the patient’s own bone marrow needs no donor matching and no immunosuppression.Read more - Science
The platform, in five parts
Autologous cellular therapy, MSC-NTF cells, cell production, the exosome platform and the intellectual property behind them.Back to Science
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.